Preclinical Efficacy Testing of New Drug Candidates

被引：48

作者：

Nuermberger, Eric L. ^{[1
,2
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21231 USA

[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21231 USA

来源：

MICROBIOLOGY SPECTRUM | 2017年 / 5卷 / 03期

关键词：

MYCOBACTERIUM-TUBERCULOSIS INFECTION; MULTIDRUG-RESISTANT TUBERCULOSIS; FIBER SYSTEM MODEL; MOXIFLOXACIN-CONTAINING REGIMENS; EARLY BACTERICIDAL ACTIVITY; GUINEA-PIG MODEL; MOUSE MODEL; STERILIZING ACTIVITY; LATENT TUBERCULOSIS; RABBIT MODEL;

D O I：

10.1128/microbiolspec.TBTB2-0034-2017

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

This is a review of the preclinical efficacy testing of new antituberculosis drug candidates. It describes existing dynamic in vitro and in vivo models of antituberculosis chemotherapy and their utility in preclinical evaluations of promising new drugs and combination regimens, with an effort to highlight recent developments. Emphasis is given to the integration of quantitative pharmacokinetic/pharmacodynamic analyses and the impact of lesion pathology on drug efficacy. Discussion also includes in vivo models of chemotherapy of latent tuberculosis infection.

引用

页数：22

共 50 条

[1] The minipig in safety testing of new drug candidates
Svendsen, O
DRUG METABOLISM REVIEWS, 2002, 34 : 41 - 41
[2] Canine organoids for drug efficacy and safety testing: an innovative preclinical model for drug development
Mochel, J. P.
Jergens, A. E.
Chandra, L.
Kingsbury, D.
Atherly, T.
Mochel, A.
Fernandez-Zapico, M. E.
Wang, K.
Kim, H. J.
Allenspach, K.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2018, 41 : 68 - 68
[3] Multidisciplinary Preclinical Investigations on Three Oxamniquine Analogues as New Drug Candidates for Schistosomiasis
Buchter, Valentin
Ong, Yih Ching
Mouvet, Francois
Ladaycia, Abdallah
Lepeltier, Elise
Rothlisberger, Ursula
Keiser, Jennifer
Gasser, Gilles
CHEMISTRY-A EUROPEAN JOURNAL, 2020, 26 (66) : 15232 - 15241
[4] Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design
Brink, Andreas
Pahler, Axel
Funk, Christoph
Schuler, Franz
Schadt, Simone
DRUG DISCOVERY TODAY, 2017, 22 (05) : 751 - 756
[5] Preclinical development of a new class of orally active drug candidates for the treatment of RSV infections
Luttick, Angela
Lin, Bo
Morton, Craig
Tucker, Simon
Bond, Silas
Draffan, Alistair
Lambert, John
Lim, Chin-Yu
Mitchell, Jeff
Sanford, Vanessa
Ryan, Jane
Kerr, Annette
Iswaran, Jega
Suzich, Joann
McCarthy, Mike
ANTIVIRAL RESEARCH, 2007, 74 (03) : A55 - A55
[6] Use of Preclinical Models to Assess the Therapeutic Potential of New Drug Candidates for Bladder Cancer
Amit, Doron
Gofrit, Ofer N.
Matouk, Imad
Birman, Tatiana
Hochberg, Abraham
SEMINARS IN ONCOLOGY, 2012, 39 (05) : 534 - 542
[7] Use of xenografts for preclinical drug testing
De Lange, M. J.
Nemati, F.
Versluis, M.
Jager, M. J.
Luyten, G. P. M.
Decaudin, D.
Van der Velden, P. A.
ACTA OPHTHALMOLOGICA, 2013, 91
[8] Use of xenografts for preclinical drug testing
De lange, Mark J.
Nemati, Fariba
Versluis, Mieke
Jager, Martine J.
Luyten, Gre P. M.
Decaudin, Didier
van der Velden, Pieter A.
CANCER RESEARCH, 2014, 74 (19)
[9] When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data
Pulley, Jill M.
Jerome, Rebecca N.
Zaleski, Nicole M.
Shirey-Rice, Jana K.
Pruijssers, Andrea J.
Lavieri, Robert R.
Chettiar, Somsundaram N.
Naylor, Helen M.
Aronoff, David M.
Edwards, David A.
Niswender, Colleen M.
Dugan, Laura L.
Crofford, Leslie J.
Bernard, Gordon R.
Holroyd, Kenneth J.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2017, 15 (08) : 354 - 361
[10] New models of breast and lung cancer bone metastases for preclinical efficacy testing
Suominen, Mari I.
Hagemann, Urs B.
Konkol, Yvonne
Bernoulli, Jenni
Fagerlund, Katja M.
Bjerke, Roger M.
Karlsson, Jenny
Halleen, Jussi M.
Cuthbertson, Alan
CANCER RESEARCH, 2016, 76

← 1 2 3 4 5 →